Timur Ilgamovich Musin

Timur Ilgamovich Musin

Auto-generated profile, based on publicly available information

Timur Ilgamovich Musin

Bashkir State Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NZNaufal Zagidullin
Naufal Zagidullin
LMLukas J. Motloch
Lukas J. Motloch
TMTimur Ilgamovich Musin
Timur Ilgamovich Musin
ZBZilya Adibovna Bagmanova
Zilya Adibovna Bagmanova
ILIrina Alexandrovna Lakman
Irina Alexandrovna Lakman
VPValentin Nikolaevich Pavlov
Valentin Nikolaevich Pavlov
J-waves represent a common finding in routine ECGs (5–6%) and are closely linked to ventricular tachycardias. While arrhythmias and non-specific ECG alterations are a frequent finding in COVID-19, an analysis of J-wave incidence in acute COVID-19 is lacking. A total of 386 patients consecutively, hospitalized due to acute COVID-19 pneumonia were included in this retrospective analysis. Admission ECGs were analyzed, screened for J-waves and correlated to clinical characteristics and 28-day mortality. J-waves were present in 12.2% of patients. Factors associated with the presence of J-waves were old age, female sex, a history of stroke and/or heart failure, high CRP levels as well as a high BMI. Mortality rates were significantly higher in patients with J-waves in the admission ECG compared to the non-J-wave cohort (J-wave: 14.9% vs. non-J-wave 3.8%, p = 0.001). After adjusting for confounders using a multivariable cox regression model, the incidence of J-waves was an independent predictor of mortality at 28-days (OR 2.76 95% CI: 1.15–6.63; p = 0.023). J-waves disappeared or declined in 36.4% of COVID-19 survivors with available ECGs for 6–8 months follow-up. J-waves are frequently and often transiently found in the admission ECG of patients hospitalized with acute COVID-19. Furthermore, they seem to be an independent predictor of 28-day mortality.

7 July 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
RGR. M. Gumerov
R. M. Gumerov
DGDiana Gareeva
Diana Gareeva
PDP. A. Davtyan
P. A. Davtyan
RRR. F. Rakhimova
R. F. Rakhimova
TMT. I. Musin
T. I. Musin
NZNaufal Zagidullin
Naufal Zagidullin
The coronavirus disease 2019 (COVID-19) affects not only the respiratory system, but also the cardiovascular system in 20-28% of cases, causing endothelial dysfunction, vasculitis, hyper- and hypocoagulation, myocarditis, endothelial dysfunction and other adverse effects. The presence of cardiovascular risk factors and diseases has been shown to worsen the disease severity and increase mortality from COVID-19. Recent studies have also found that elevations in some serum cardiovascular biomarkers can stratify the disease severity, in particular rates of hospitalizations to an internal medicine or intensive care unit, intubation, and mortality. They can be divided into markers of damage (TnT/I, creatine phosphokinase (CPK) and CPK-MB, myoglobin, NT-proBNP), coagulation (prothrombin time, fibrinogen and D-dimer), as well as prospective biomarkers for which the available evidence base is limited but there is a pathophysiological rationale (homocysteine and sST2). This review presents studies on the use of above serum biomarkers to stratify the risk of death in patients with COVID-19.

15 March 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
TMT. I. Musin
T. I. Musin
ZBZ. A. Bagmanova
Z. A. Bagmanova
VPValentin Nikolaevich Pavlov
Valentin Nikolaevich Pavlov
RGR. M. Gumerov
R. M. Gumerov
ATAnton Tyurin
Anton Tyurin
NZNaufal Zagidullin
Naufal Zagidullin
The classic Osborn wave in the form of characteristic changes at the depolarization end or ventricular repolarization beginning is more often associated with hypothermia (body temperature below 35,6° C). Some researchers have noticed Osborn wave at normal body temperature, various pathological conditions and diseases: hypercalcemia, myocardial ischemia, postoperative pericarditis, with central nervous system, etc. We presented a case report of a 72-year-old female inpatient with moderate COVID-19, confirmed by polymerase chain reaction, and 48% lung damage. Before admission to the hospital, electrocardiogram had no Osborn wave, which first appeared at admission. There was a significant increase in serum C-reactive protein and a moderate increase in serum biomarkers and no changes in intervals and segments on the electrocardiogram. The appearance of Osborn wave may be associated with intramyocardial electrolyte imbalance, a consequence of antiviral and antibacterial therapy that violate intraventricular conduction.

7 July 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
TMT. I. Musin
T. I. Musin
ZBZ. A. Bagmanova
Z. A. Bagmanova
DGD. A. Gareev
D. A. Gareev
VRV. G. Rudenko
V. G. Rudenko
NZNaufal Zagidullin
Naufal Zagidullin
Aim. To evaluate the dynamics of left atrial volume (LAV), strain (S) during the reservoir phase and strain rate (SR) in patients with paroxysmal and persistent atrial fibrillation (AF), scheduled for catheter radiofrequency ablation (RFA), as well as to compare the predictive value of S and SR as a marker of maintaining sinus rhythm.Material and methods. A total of 19 patients (men, 11; women, 8) aged 62±10,7 years with AF were included in the study, 13 (67%) of whom had persistent AF, while 6 patients (33%) had paroxysmal AF Two-dimensional and speckle tracking N. Sh. echocardiography (EPIQ 7, Philips) were performed in all patients before ablation and 12 months after RFA.Results. The patients were divided into 2 groups: group 1 — no recurrent AF after RFA (n=12; 63%); group 2 — recurrent AF after RFA (n=7; 37%). According to 2D echocardiography, the baseline values of LAV and LAV index (LAVI) did not significantly differ between groups 1 and 2: 56,0±12,6 ml and 52,0±23,2 ml (p=0,78); 28,0±7,8 ml/m2 and 25,1±13,6 ml/m2 (p=0,85), respectively. The initial S values of the LA in the four-chamber (4C-) and two-chamber (2C-) apical views in group 1patients were higher than in those from group 2: 4C-S, 34,3±9,9% and 16,9±4,4% (p=0,0008); 2C-S, 29,2±8,3% and 14,5±4,4% (p=0,0011), respectively. Baseline SR values were higher in group 1 patients compared with group 2 in 4C- and 2C-views: 4C-SR, 2,36±0,37 s-1 and 1,39±0,50 s-1 (p=0,0013); 2C-SR 2,09±0,39 s-1 and 1,4±0,53 s-1 (p=0,0053), respectively. The LAV in group 1 became significantly less after RFA than its initial levels: 56,0±12,6 ml and 47,0±12,1 ml (p=0,008). The LAVI also significantly decreased 12 months after RFA as follows: 28,0±7,8 ml/m2 and 22,6±8,3 ml/m2 (p=0,02). In group 2, there was no decrease in either LAV or LAVI after 12 months: LAV, 52,0±23,2 ml and 54,0±12,1 ml (p=1,0); LAVI, 25,1±13,6 ml/m2 and 30,9±7,6 ml/m2 (p=0,3). In group 1, there was no significant change in LA S 12 months after RFA: 4C-S, 34,3±9,9% and 30,3±9,6% (p=0,287); 2C-S, 29,2±8,3% and 28,9±9,1% (p=0,82). In group 2, LA S levels in 4C- and 2C-views did not significantly change depending on the performed RFA procedure: 4C-S, 16,9±4,4% and 17,4±6,2% (p=0,12); 2C-S, 14,5±4,4% and 16,5±6,8% (p=1,0). According to the ROC analysis, the optimal cut-off values for baseline 4C-SR (1,8 s-1 (AUC=0,958)), 2C-SR (1,75 s-1 (AUC=0,899)), 4C-S (20,7% (AUC=0,976)), and 2C-S (19,2% (AUC=0,964)) were reliable individual predictors of sinus rhythm maintenance.Conclusion. A stable sinus rhythm 12 months after the RFA was maintained in patients with higher baseline LA S and SR levels. The baseline LA S and SR values have a high predictive value for AF recurrence in patients after RFA. In patients with effective RFA, LAV and LAVI decreased without changing the S and SR. There was no effect of LA reverse remodeling and improvement in LA S values in patients with recurrent AF after RFA.

18 April 2022 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
PDF file
ILIrina Lakman
Irina Lakman
TMTimur I. Musin
Timur I. Musin
AGAliya R. Galiullina
Aliya R. Galiullina
ZBZilya A. Bagmanova
Zilya A. Bagmanova
RGRuslan M. Gumerov
Ruslan M. Gumerov
ЦБЦай Бенджи
Цай Бенджи
Background. The COVID-19 pandemic is associated with significant number of complications and mortality and a burden on the healthcare system. In 1015% of hospitalized patients, the invasive and non-invasive mechanical ventilation (IMV/NIMV) is required. At the same time, it is important to stratify the risk of mechanical ventilation upon admission to the hospital. Aims to identify clinical and laboratory risk factors for transfer to IMV and NIMV in hospitalized patients with COVID-19-associated pneumonia. Methods. A retrospective one-center nonrandomized study of 386 consecutive hospitalized patients with COVID-19-associated pneumonia was performed. The primary endpoints were IMV (n=22) and NIMV (n=28). Risk factors of artificial ventilation were considered for periods up to 14 and 28 days for both variants. To select a risk predictor, a univariate analysis based on Cox survival regression was performed, followed by multivariate analysis to determine risk factors at these time points. Results. After 28 days from admission the mortal exit was registered in 20 patients from 386 patients (5.2%). 22 patients (5.7%) were transferred to IMV, and 28 patients (7.3%) to NIV, and 9 of the latter were transferred later to IMV. As a result of univariate and multivariate analyzes, the risk factors for transfer to mechanical ventilation on 14th day were: age 65 years (OR=5.91), a history of stroke (OR=17.04), an increased serum level of urea (OR=6.36), LDH (OR=7.39), decreased sodium (OR=12.32), GFR 80 mL/min/1.73 m2 (OR=13.75) and platelets (OR=4.14); on the 28th day age 65 years (OR=4.58), J-wave on the ECG (OR=2.98), an increase of LDH (OR=9.99) and a decrease in albumin (OR=2.77) in serum. Predictors of the transfer of patients with COVID-19 to NIV within the period up to 14 days from the beginning of hospitalization were the age 65 years (OR=5.09), procalcitonin level in the blood 0.25 ng/ml (OR=0.19), leukocytes 11109 (OR=19.64) and increased LDH (OR=3.9). Conclusions. In patients with COVID-19, the risk factors for transfer to IMV/NIVL in the period of 14 and 28 days from the beginning of hospitalization were identified, which enable patients mechanical ventilation stratification and to plan respiratory support resources.

14 December 2020 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
DGDiana Gareeva
Diana Gareeva
TMT. I. Musin
T. I. Musin
VPValentin Nikolaevich Pavlov
Valentin Nikolaevich Pavlov
PDP. A. Davtyan
P. A. Davtyan
VIV. Sh. Ishmetov
V. Sh. Ishmetov
ККК. Карвальо
К. Карвальо
The COVID-19 pandemic has had a huge impact on the health of millions of people around the world on an unprecedented scale. Unfortunately, the process of creating effective antiviral drugs and vaccines is being delayed. Therefore, drugs that are already available and may have an effect on COVID-19 are being investigated. Due to the fact that viral infection often affects the cardiovascular system, causing myocardial infarction, viral myocarditis, tachyarrhythmias and stress cardiomyopathies, a theory was put forward that HMG-CoA reductase (3-hydroxy-3methyl-glutaryl-CoA reductase) inhibitors (statins) can reduce the risk of cardiovascular complications in these patients. In recent years, this class of drugs has been proposed, including for viral infections, such as the influenza virus or MERS-CoV. The review discusses both the latest clinical data on the efficacy of statins in COVID-19 and the pleotropic mechanisms of statins that can limit the pathogenic effect of viruses. In particular, statins can act on lipid cell rafts (subdomains of the plasma membrane), decreasing their lipid concentration; limiting the interaction of the virus with the receptors of angiotensin-converting enzyme-2 and CD-147. Statins have an antiinflammatory effect (blocking the molecular mechanisms of inflammation, including NF-κB and NLRP3), limit the development of a “cytokine storm” in severe patients with COVID-19; can inhibit SARS-CoV-2 basic protease; influence coagulation, limit sympathetic activity and have other effects. In two large cohort observational studies (n = 96032 and n = 13981), hospitalized patients with COVID-19 who were taking statins showed a decrease in hospital mortality and mortality 28 days after the admission to the hospital. Thus, statins can play a role in the treatment of COVID-19.